Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BLTE 
Belite Bio Inc ADR (BLTE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BLTE (1-star) is a SELL. SELL since 3 days. Profits (0.18%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $93.75
1 Year Target Price $93.75
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 30.83% | Avg. Invested days 38 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.12B USD | Price to earnings Ratio - | 1Y Target Price 93.75 |
Price to earnings Ratio - | 1Y Target Price 93.75 | ||
Volume (30-day avg) 5 | Beta -1.5 | 52 Weeks Range 43.70 - 86.53 | Updated Date 08/29/2025 |
52 Weeks Range 43.70 - 86.53 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.39 | Actual -0.31 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -11.68% | Return on Equity (TTM) -17.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1973470763 | Price to Sales(TTM) - |
Enterprise Value 1973470763 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -35.61 | Shares Outstanding 32833400 | Shares Floating 15173343 |
Shares Outstanding 32833400 | Shares Floating 15173343 | ||
Percent Insiders 53.45 | Percent Institutions 0.74 |
Upturn AI SWOT
Belite Bio Inc ADR
Company Overview
History and Background
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for inherited retinal diseases with unmet medical needs like Stargardt disease. Founded to address genetic eye disorders, they've progressed from preclinical studies to clinical trials.
Core Business Areas
- Therapeutic Development: Focuses on developing innovative therapies for orphan inherited retinal degenerative diseases with unmet medical needs.
- Clinical Trials: Conducts clinical trials for their lead product candidates, evaluating safety and efficacy.
Leadership and Structure
Key personnel include the CEO, CSO, and other executives overseeing R&D, clinical operations, and business development. The company follows a standard biotech organizational structure.
Top Products and Market Share
Key Offerings
- Tinlarebant (LBS-008): An oral therapy in clinical development for Stargardt disease and other ABCA4-related retinal diseases. It aims to reduce the buildup of toxic vitamin A byproducts in the eye. Market share data is not publicly available as it is still in development. Key competitors include companies developing gene therapies and other novel treatments for retinal diseases.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a growing focus on gene therapies and rare diseases. The ophthalmic drug market is driven by aging populations and increasing prevalence of retinal diseases.
Positioning
Belite Bio is positioned as a specialist in developing treatments for orphan inherited retinal diseases. Their competitive advantage lies in their expertise in ABCA4-related retinopathies and their oral therapy approach.
Total Addressable Market (TAM)
The total addressable market for Stargardt disease and related retinal disorders is estimated to be in the billions of dollars, with significant unmet needs. Belite Bio aims to capture a portion of this market with Tinlarebant.
Upturn SWOT Analysis
Strengths
- Targeting significant unmet medical needs
- Oral therapy approach offers convenience
- Advanced stage clinical development of lead compound
- Expertise in ABCA4-related retinopathies
Weaknesses
- Single product focus increases risk
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
- High cash burn rate
Opportunities
- Expansion of pipeline with new drug candidates
- Partnerships with larger pharmaceutical companies
- Regulatory approval and commercialization of Tinlarebant
- Expanding label for Tinlarebant to include other retinal diseases
Threats
- Clinical trial failures
- Competition from gene therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- ALNY
- VRTX
- CRSP
Competitive Landscape
Belite Bio faces competition from companies developing gene therapies and other novel treatments. Their oral therapy approach provides a unique advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal as the company is pre-revenue.
Future Projections: Future growth depends on clinical trial results and regulatory approval of Tinlarebant. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing clinical trials for Tinlarebant, including Phase 3 studies.
Summary
Belite Bio Inc ADR is a clinical-stage biopharmaceutical company specializing in inherited retinal diseases. Their lead product, Tinlarebant, targets Stargardt disease and related conditions. The company's success hinges on positive clinical trial outcomes and regulatory approval. Their competitive advantage is in oral therapy but it is pre-revenue and faces competition from bigger players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Belite Bio Inc ADR
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2022-04-29 | Chairman of the Board of Directors & CEO Dr. Yu-Hsin Lin M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://www.belitebio.com |
Full time employees 25 | Website https://www.belitebio.com | ||
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.